ACP: Use GLP-1 agonists or SGLT-2 inhibitors as add-on therapies for type 2 diabetes
BOSTON — New recommendations from ACP on type 2 diabetes treatment include adding a GLP-1 agonist or SGLT-2 inhibitor to therapy for patients who have inadequate glycemic control, the organization announced.During her presentation at the ACP Internal Medicine Meeting, Carolyn Crandall, MD, MS, MACP, chair of the ACP clinical guidelines committee and a clinical professor of medicine at the